Investors Face August 10 Deadline in Erasca Securities Class Action
Investors who purchased Erasca, Inc. shares between January 14, 2025, and April 26, 2026, have until August 10, 2026, to seek lead plaintiff status in a pending securities class action lawsuit filed in the United States District Court for the Southern District of California.
The litigation, titled Cheng v. Erasca, Inc. (No. 26-cv-03481), alleges that the company and its executives violated federal securities laws by withholding material information. Specifically, the complaint claims that positive public statements regarding the firm's ERAS-0015 product—a pan-RAS molecular glue intended for solid tumors—lacked a reasonable basis. The suit contends that preclinical data for the drug relied on improper comparisons to Revolution Medicines, Inc., potentially exposing Erasca to patent and trade secret disputes.
Kahn Swick & Foti, LLC, a boutique firm led by former Louisiana Attorney General Charles C. Foti, Jr., is representing the class. Managing Partner Lewis Kahn is overseeing investor outreach, with the firm encouraging those who suffered losses during the specified period to contact them at 1-877-515-1850 or via their website. While the court deadline for appointment as a lead plaintiff is August 10, investors are not required to serve in that capacity to potentially share in any eventual recovery.
Comments (0)
No comments yet. Be the first!